AB Science plummets on second CHMP rejection for canine anticancer
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's committee for medicinal products for human use ( CHMP) has turned down AB Science's application to market pancreatic cancer drug Masiviera (masitinib) in Europe.
You may also be interested in...
Helsinn And AB Science Persevere In EU Despite CHMP Setback
Helsinn and AB Science plan to conduct additional studies with their products the CHMP turned down this month, in an effort to secure eventual EU approval in the rejected indications. A third company, XBiotech, hasn’t ruled out similar action. New MAAs would be required.
Building The Talent Pipeline Starts With Access For All
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
Snapshot: October Highlights
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.
Need a specific report? 1000+ reports available
Buy Reports